These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28571579)

  • 21. [Advancement in the research of mechanism of immune dysfunction in sepsis and the regulatory effects of Xuebijing injection].
    Gao YL; Chai YF; Yao YM
    Zhonghua Shao Shang Za Zhi; 2013 Apr; 29(2):162-5. PubMed ID: 23985206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
    Delano MJ; Ward PA
    J Clin Invest; 2016 Jan; 126(1):23-31. PubMed ID: 26727230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The beginning of personalized medicine in sepsis: small steps to a bright future.
    Christaki E; Giamarellos-Bourboulis EJ
    Clin Genet; 2014 Jul; 86(1):56-61. PubMed ID: 24579691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms and modulation of sepsis-induced immune dysfunction in children.
    Mithal LB; Arshad M; Swigart LR; Khanolkar A; Ahmed A; Coates BM
    Pediatr Res; 2022 Jan; 91(2):447-453. PubMed ID: 34952937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Janus face of complement-driven neutrophil activation during sepsis.
    Halbgebauer R; Schmidt CQ; Karsten CM; Ignatius A; Huber-Lang M
    Semin Immunol; 2018 Jun; 37():12-20. PubMed ID: 29454576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of innate immune responses in the treatment of sepsis and pneumonia.
    Schultz MJ; van der Poll T
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):11-7. PubMed ID: 15032638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The gastrointestinal immune system: Implications for the surgical patient.
    Pierre JF; Busch RA; Kudsk KA
    Curr Probl Surg; 2016 Jan; 53(1):11-47. PubMed ID: 26699624
    [No Abstract]   [Full Text] [Related]  

  • 28. The Immunomodulatory and Therapeutic Effects of Mesenchymal Stromal Cells for Acute Lung Injury and Sepsis.
    Ho MS; Mei SH; Stewart DJ
    J Cell Physiol; 2015 Nov; 230(11):2606-17. PubMed ID: 25913273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies against RAGE in sepsis and inflammation: implications for therapy.
    Lutterloh EC; Opal SM
    Expert Opin Pharmacother; 2007 Jun; 8(9):1193-6. PubMed ID: 17563255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Interventions: What's New and the Future.
    Vincent JL; Grimaldi D
    Crit Care Clin; 2018 Jan; 34(1):161-173. PubMed ID: 29149938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunology programs must include sepsis.
    Monneret G
    Science; 2010 May; 328(5982):1106. PubMed ID: 20508115
    [No Abstract]   [Full Text] [Related]  

  • 32. [End-organ damage in inflammation and sepsis].
    Müller-Werdan U; Werdan K
    Internist (Berl); 2003 Jul; 44(7):864-71. PubMed ID: 14631582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunomodulatory effect of extracorporeal hemocorrection in patients with surgical sepsis].
    Borovkova NV; Aleksandrova IV; Khvatov VB; Reĭ SI; Il'inskiĭ ME; Abakumov MM
    Anesteziol Reanimatol; 2009; (3):37-40. PubMed ID: 19663221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunomodulation for sepsis: a change of tack?].
    Leentjens J; Kox M; Pickkers P
    Ned Tijdschr Geneeskd; 2014; 158():A6859. PubMed ID: 24518844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of immune response-derived biomarkers in the differential diagnosis of inflammatory disorders.
    ten Oever J; Netea MG; Kullberg BJ
    J Infect; 2016 Jan; 72(1):1-18. PubMed ID: 26429736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era.
    Behrens EM; Koretzky GA
    Arthritis Rheumatol; 2017 Jun; 69(6):1135-1143. PubMed ID: 28217930
    [No Abstract]   [Full Text] [Related]  

  • 37. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.
    Chao YH; Wu HP; Wu KH; Tsai YG; Peng CT; Lin KC; Chao WR; Lee MS; Fu YC
    PLoS One; 2014; 9(10):e110338. PubMed ID: 25337817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controversies in neonatal sepsis: immunomodulation in the treatment and prevention of neonatal sepsis.
    Moss SJ; Gennery AR
    Adv Exp Med Biol; 2006; 582():71-83. PubMed ID: 16802620
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunomodulatory therapies in sepsis.
    Kox WJ; Volk T; Kox SN; Volk HD
    Intensive Care Med; 2000; 26 Suppl 1():S124-8. PubMed ID: 10786969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulation in polytrauma and polymicrobial sepsis - where do we stand?
    Neunaber C; Zeckey C; Andruszkow H; Frink M; Mommsen P; Krettek C; Hildebrand F
    Recent Pat Inflamm Allergy Drug Discov; 2011 Jan; 5(1):17-25. PubMed ID: 21158733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.